Trial Profile
A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to Evaluate Plasma-Derived Antihaemophilic Factor/Von Willebrand Factor Concentrate (Biostate) for Immune Tolerance Induction in Male Paediatric Subjects With Haemophilia A (less than or equal to 2%) Who Have Developed High-titre Antibodies to Factor VIII (Factor VIII Inhibitors)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms SWIFT-ITI
- Sponsors CSL Behring
- 16 Dec 2021 This trials has been completed in France, according to European Clinical Trials Database record.
- 10 Nov 2014 New trial record